Analysts Set Simulations Plus, Inc. (NASDAQ:SLP) Target Price at $24.40

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $24.40.

Several brokerages have commented on SLP. KeyCorp lowered shares of Simulations Plus from an “overweight” rating to a “sector weight” rating in a report on Tuesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Simulations Plus in a report on Wednesday, October 8th. TD Cowen began coverage on shares of Simulations Plus in a report on Tuesday, September 30th. They issued a “hold” rating and a $16.00 price objective for the company. Stephens decreased their price objective on shares of Simulations Plus from $28.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, July 15th. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Tuesday, July 15th.

Simulations Plus Stock Up 2.2%

Shares of SLP opened at $15.60 on Thursday. Simulations Plus has a twelve month low of $12.39 and a twelve month high of $37.67. The stock has a market capitalization of $314.03 million, a P/E ratio of -4.95 and a beta of 0.99. The firm has a fifty day simple moving average of $14.76 and a two-hundred day simple moving average of $20.92.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Monday, July 14th. The technology company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.26 by $0.19. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 11.62%. The business had revenue of $20.36 million during the quarter, compared to analyst estimates of $22.83 million. During the same period in the prior year, the business earned $0.27 EPS. The company’s revenue for the quarter was up 9.8% on a year-over-year basis. Sell-side analysts expect that Simulations Plus will post 1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SLP. GAMMA Investing LLC increased its stake in shares of Simulations Plus by 20,727.1% in the 1st quarter. GAMMA Investing LLC now owns 17,703 shares of the technology company’s stock worth $434,000 after acquiring an additional 17,618 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Simulations Plus by 2.1% in the 1st quarter. Rhumbline Advisers now owns 66,222 shares of the technology company’s stock worth $1,624,000 after acquiring an additional 1,334 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of Simulations Plus by 33.8% in the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock worth $36,000 after acquiring an additional 375 shares in the last quarter. Azzad Asset Management Inc. ADV bought a new position in shares of Simulations Plus in the 1st quarter worth about $436,000. Finally, North Star Investment Management Corp. bought a new position in shares of Simulations Plus in the 1st quarter worth about $1,300,000. 78.08% of the stock is currently owned by institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.